{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"LN-145"},{"type":"Synonym","name":"autologous TILs LN-145"},{"type":"Synonym","name":"autologous tumor-infiltrating lymphocytes LN-145"},{"type":"CodeName","name":"LN145"}],"definition":{"html":"A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.","text":"A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells."},"drugInfoSummaryLink":null,"nciConceptId":"C135634","nciConceptName":"Autologous Tumor Infiltrating Lymphocytes LN-145","termId":789043,"name":"autologous tumor infiltrating lymphocytes LN-145","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"autologous-tumor-infiltrating-lymphocytes-ln-145"},{"aliases":[{"type":"Synonym","name":"autologous TILs LN-145-S1"},{"type":"Synonym","name":"LN145-S1"},{"type":"Synonym","name":"autologous tumor-infiltrating lymphocytes LN-145-S1"},{"type":"CodeName","name":"LN 145-S1"},{"type":"CodeName","name":"LN-145-S1"}],"definition":{"html":"A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating and antineoplastic activities. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145-S1 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.","text":"A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating and antineoplastic activities. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145-S1 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells."},"drugInfoSummaryLink":null,"nciConceptId":"C173508","nciConceptName":"Autologous Tumor Infiltrating Lymphocytes LN-145-S1","termId":802231,"name":"autologous tumor infiltrating lymphocytes LN-145-S1","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"autologous-tumor-infiltrating-lymphocytes-ln-145-s1"}],"links":null}